Russia says Sputnik V vaccine over 95 pc effective against COVID-19


Team Udayavani, Nov 24, 2020, 5:31 PM IST

New Delhi: Russia on Tuesday said that the efficacy of its Sputnik V COVID-19 vaccine is over 95 per cent and the cost of one dose of the shot for international markets will be less than USD 10 (around Rs 740).

Preliminary data from volunteers obtained 42 days after the first dose (corresponds with 21 days after the second dose) indicates the efficacy of the vaccine above 95 per cent, the Gamelya National Centre and the Russian Direct Investment Fund (RDIF) said in a joint statement.

“The cost of one dose of the Sputnik V vaccine for international markets will be less than USD 10. It is a double dose vaccine,” the statement said.

The efficacy of the Sputnik V vaccine is 91.4 per cent, based on the second interim analysis of data obtained 28 days after administering the first dose (seven days after the second dose), it added.

The positive results were obtained during the second interim data analysis of the largest double-blind, randomised, placebo-controlled Phase III clinical trials in Russia’s history involving 40,000 volunteers, the statement said.

In October pharma major Dr Reddy’s Laboratories and RDIF had received approval from the Drugs Controller General of India (DCGI) to conduct an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India.

The next interim data analysis will be conducted upon reaching the third control point of 78 confirmed coronavirus cases among the study participants. Final data analysis will be available by the end of Phase III clinical trials, the statement said.

As of November 24, more than 22,000 volunteers were vaccinated with the first dose and more than 19,000 volunteers with the first and the second dose of the vaccine at 29 medical centres in Russia as part of the ongoing clinical trials, it added.

“Currently Phase III clinical trials are approved and are ongoing in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India,” the statement said.

As of November 24, no unexpected adverse events were identified as part of the research, it added.

“The data demonstrating high efficacy of the Sputnik V vaccine gives us hope that we will soon obtain the most important tool in the fight against the pandemic of the novel coronavirus infection,” Minister of Health of the Russian Federation Mikhail Murashko said.

In a similar vein, Gamaleya Center Director Alexander Gintsburg said: “It is very important that the second interim efficacy analysis of Sputnik V has confirmed our findings from the first stage and shown its efficacy at 91-92%”.

“Let me stress that the second analysis was conducted a week after volunteers got the second dose, meaning that their bodies have partially reacted to both doses”, he added.

Requests for more than 1.2 billion doses of Sputnik V vaccine came from more than 50 countries. The vaccine supplies for the global market will be produced by RDIF”s international partners in India, Brazil, China, South Korea and other countries, the statement said.

The current agreements between RDIF and leading foreign pharmaceutical companies allow the Sputnik V vaccine to be produced abroad for 500 million people per year, starting from 2021, it added.

“The Gamaleya Center has developed one of the most efficient vaccines against coronavirus in the world with an efficacy rate of more than 90 per cent,” Russian Direct Investment Fund CEO Kirill Dmitriev said.

Dr Reddy’s Laboratories in October has also announced a partnership with the Biotechnology Industry Research Assistance Council (BIRAC), set up by the Department of Biotechnology, for advisory support on clinical trials of Russian COVID-19 vaccine, Sputnik V, in India.

On Monday pharma major AstraZeneca had said an interim analysis of clinical trials of its COVID-19 vaccine in the UK and Brazil showed that it was 70 per cent effective on average.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

Maha: One dead in road accident in Chandrapur district

China says latest round of talks with India on border issue ‘positive and constructive’; slams White House official’s remarks

Karnataka legislature joint session from Feb 14, budget in March first week

He didn’t want the money, he just wanted to play: Looking back at Deepak Hooda’s rollercaster ride

‘Badhaai Do’ humour not at the expense of LGBTQI community, it’s a sensitive film: Bhumi Pednekar

‘Goonda raj’ to return if Akhilesh forms govt in UP: Shah

Hockey legend Charanjit Singh dies


Related Articles More

China says latest round of talks with India on border issue ‘positive and constructive’; slams White House official’s remarks

Terrorist entities shouldn’t get any support from Afghan soil or terror sanctuaries based in region: India

Voters value honesty in their politicians above all else – new study

North Korea fires 2 suspected missiles in 6th launch in 2022

Capsized boat found near Florida; 39 people missing

MUST WATCH

History and Significance of Barkur

Udayavani News Bulletin 27-1-2022

A Crow In Obalapura Village In Chitradurga Is Attacking 7 People

DK Shivakumar Press meet

Hindu Vahini members manhandled, detained by Guntur Police


Latest Additions

Maha: One dead in road accident in Chandrapur district

Kerala witnessing Omicron wave, says Minister

Man gunned down in high-security area of Ranchi

China says latest round of talks with India on border issue ‘positive and constructive’; slams White House official’s remarks

Nadda forms 4-member panel to probe TN girl’s death by suicide

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.